Glenmark Pharmaceuticals Reaches $7M Settlement in US Antitrust Lawsuits Over Cholesterol Drugs
• Glenmark Pharmaceuticals has agreed to pay $7 million to settle antitrust lawsuits with three major healthcare entities - Humana, Centene, and Kaiser - over generic cholesterol medications Zetia and Vytorin.
• The lawsuits alleged that Glenmark entered an anticompetitive agreement in 2010 with Schering Corporation and MSP Singapore Company LLC regarding patent infringement litigation for ezetimibe.
• While reaching the settlement agreement, Glenmark explicitly denies all allegations and maintains the settlement does not indicate any admission of liability or illegal conduct.
Vaccinex's Pepinemab Shows Promise in Alzheimer's Disease Trial
• Vaccinex will present new data from its SIGNAL-AD Phase 1b/2 trial of pepinemab for Alzheimer's disease at the CTAD conference.
• The study evaluates pepinemab's impact on cognitive decline and biomarkers of disease progression by blocking SEMA4D.
• Preclinical models suggest pepinemab may have beneficial effects on brain vasculature, potentially avoiding toxicity in Alzheimer’s disease.
• Pepinemab is designed to block SEMA4D, aiming to prevent damaging inflammation and slow disease progression in the brain.
© Copyright 2025. All Rights Reserved by MedPath